Business & Growth
Business & Growth
Two Bets on Complex Molecules, One Asset Light Model
HRV Pharma is planning a ₹150 crore investment in peptides and high-potency APIs through a dedicated peptide programme and a joint venture focused on specialised oncology molecules. Both initiatives follow the company's asset-light model, retaining intellectual property, regulatory assets and commercial rights while working with specialist manufacturing partners.
Trust Isn't a Feeling. It's a System.
How can a pharmaceutical company maintain quality without owning its manufacturing plants? HRV Pharma builds trust through standardised audits, real-time performance tracking and continuous visibility across 53 partners, helping identify issues before they become shipment or regulatory problems.
Not a Capacity Problem, a Utilisation Problem
When Hari Kiran Chereddi founded HRV Pharma in 2016, he saw an opportunity to address underutilised pharmaceutical manufacturing capacity in India. In this ET Now interview, he explains HRV's asset-light model, its quality assurance systems across 53 sites, and its ambition to reach ₹1,000 crore while remaining debt free.
What Indian Pharma Is Really Buying
Sun Pharma's $11.75 billion acquisition of Organon highlights a broader shift in the Indian pharmaceutical industry. Featuring insights from industry leaders, including HRV Pharma's Hari Kiran Chereddi, BioSpectrum explores the growing importance of brand value, specialty portfolios, biosimilars and access to regulated global markets.
No Factory, ₹400 Crore Revenue: How HRV Made It Happen
How does HRV Pharma generate over ₹400 crore in revenue without owning a manufacturing plant? Discover its asset-light business model, network of 50+ US FDA and EU approved manufacturing partners, and growth to 700+ customers across 55 countries.